Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report

Triple-negative breast cancer (TNBC) is highly aggressive disease that is often refractory to surgery and multiple lines of therapy. Although the repertoire of FDA-approved treatments has expanded, there is an unmet need for biomarkers that can aid in appropriate selection and timing of therapy. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Azzi, Georges, Krinshpun, Shifra, Tin, Antony, Maninder, Minu, Malashevich, Allyson Koyen, Malhotra, Meenakshi, Vega, Ruben Ruiz, Billings, Paul R., Rodriguez, Angel, Aleshin, Alexey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149406/
https://www.ncbi.nlm.nih.gov/pubmed/35702676
http://dx.doi.org/10.1159/000524324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149406/
https://www.ncbi.nlm.nih.gov/pubmed/35702676
http://dx.doi.org/10.1159/000524324

Ejemplares similares